Article
Disease monitoring of epidermal growth factor receptor (EGFR)-mutated non-small-cell lung cancer patients treated with tyrosine kinase inhibitors via EGFR status in circulating tumor DNA.
Thoracic cancer - 1 Aug 2022
Li Yan, Xu Ziyi, Wang Shouzheng, Zhu Yixiang, Ma Di, Mu Yuxin, Ying Jianming, Li Junling, Xing Puyuan
Abstract excerpt
OBJECTIVE: Circulating tumor DNA (ctDNA) monitoring proves to be a promising approach to assess response and predict survival in epidermal growth factor receptor (EGFR)-mutated non-small-cell lung cancer (NSCLC) patients treated with tyrosine kinase inhibitors (TKIs). However, whether the dynamic changes in ctDNA EGFR mutation status have the same predictive value as ctDNA remains unknown. This study aims to...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.